group VI iPLA2 Activators
The chemical class of group VI iPLA2 activators comprises a diverse array of compounds that selectively target and modulate the enzymatic activity of group VI iPLA2, influencing cellular processes associated with lipid metabolism, inflammation, and membrane dynamics. Among the activators listed, Oxozeaenol stands out as a potent inducer of group VI iPLA2 activity. Oxozeaenol achieves this activation indirectly by inhibiting TAK1, a critical kinase in the MAPK signaling pathway. Anisomycin, another activator, influences group VI iPLA2 through the modulation of the JNK signaling pathway. By promoting JNK activation, Anisomycin indirectly stimulates group VI iPLA2, enhancing arachidonic acid release and lipid signaling. Staurosporine, a kinase inhibitor, activates group VI iPLA2 through its impact on the PKC signaling pathway. By inhibiting PKC, Staurosporine indirectly promotes group VI iPLA2 activation, leading to increased arachidonic acid release and lipid signaling.
Tautomycin, a phosphatase inhibitor, influences group VI iPLA2 through its impact on the MAPK signaling pathway. By inhibiting phosphatases, Tautomycin indirectly stimulates group VI iPLA2, enhancing arachidonic acid release and lipid signaling. Okadaic Acid, a potent phosphatase inhibitor, activates group VI iPLA2 through its influence on the MAPK signaling pathway. By inhibiting phosphatases, Okadaic Acid indirectly promotes group VI iPLA2 activation, leading to increased arachidonic acid release and lipid signaling. Phorbol 12-myristate 13-acetate (PMA), a PKC activator, directly stimulates group VI iPLA2 through the PKC signaling pathway. By activating PKC, PMA enhances group VI iPLA2 activation, leading to increased arachidonic acid release and lipid signaling. Resolvin D1, a specialized pro-resolving lipid mediator, activates group VI iPLA2 by promoting the release of arachidonic acid. This direct stimulation leads to enhanced lipid signaling pathways associated with inflammation resolution. Fasudil, a Rho kinase inhibitor, activates group VI iPLA2 through its influence on the Rho/ROCK signaling pathway. By suppressing Rho kinase activity, Fasudil indirectly promotes group VI iPLA2 activation, leading to increased arachidonic acid release and lipid signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(5Z)-7-Oxozeaenol | 253863-19-3 | sc-202055 sc-202055A | 1 mg 5 mg | $154.00 $633.00 | 13 | |
(5Z)-7-Oxozeaenol is a potent activator of group VI iPLA2, acting through the inhibition of TAK1, a key kinase in the MAPK signaling pathway. By suppressing TAK1, Oxozeaenol indirectly activates group VI iPLA2, leading to increased arachidonic acid release and subsequent lipid signaling. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a compound that activates group VI iPLA2 through the modulation of the JNK signaling pathway. By promoting JNK activation, Anisomycin indirectly stimulates group VI iPLA2, enhancing arachidonic acid release and lipid signaling. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a kinase inhibitor that activates group VI iPLA2 through its impact on the PKC signaling pathway. By inhibiting PKC, Staurosporine indirectly promotes group VI iPLA2 activation, leading to increased arachidonic acid release and lipid signaling. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid is a potent phosphatase inhibitor that activates group VI iPLA2 through its impact on the MAPK signaling pathway. By inhibiting phosphatases, Okadaic Acid indirectly promotes group VI iPLA2 activation, leading to increased arachidonic acid release and lipid signaling. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a PKC activator that stimulates group VI iPLA2 through the PKC signaling pathway. By activating PKC, PMA directly enhances group VI iPLA2 activation, leading to increased arachidonic acid release and lipid signaling. | ||||||
Resolvin D1 | 872993-05-0 | sc-204877 sc-204877A | 10 µg 25 µg | $257.00 $602.00 | 1 | |
Resolvin D1 is a specialized pro-resolving lipid mediator that activates group VI iPLA2. By promoting the release of arachidonic acid, Resolvin D1 directly stimulates group VI iPLA2, enhancing lipid signaling pathways associated with inflammation resolution. | ||||||
Fasudil, Monohydrochloride Salt | 105628-07-7 | sc-203418 sc-203418A sc-203418B sc-203418C sc-203418D sc-203418E sc-203418F | 10 mg 50 mg 250 mg 1 g 2 g 5 g 10 g | $18.00 $32.00 $85.00 $165.00 $248.00 $486.00 $910.00 | 5 | |
Fasudil is a Rho kinase inhibitor that activates group VI iPLA2 through its influence on the Rho/ROCK signaling pathway. By suppressing Rho kinase activity, Fasudil indirectly promotes group VI iPLA2 activation, leading to increased arachidonic acid release and lipid signaling. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a proteasome inhibitor that activates group VI iPLA2 through its impact on NF-κB signaling. By inhibiting the proteasome, Epoxomicin indirectly stimulates group VI iPLA2, enhancing arachidonic acid release and lipid signaling associated with inflammation. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $240.00 | 9 | |
Bryostatin 1 is a PKC modulator that activates group VI iPLA2 through the PKC signaling pathway. By regulating PKC activity, Bryostatin 1 directly enhances group VI iPLA2 activation, leading to increased arachidonic acid release and lipid signaling. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $105.00 $408.00 $1224.00 | 35 | |
Leptomycin B is a CRM1 inhibitor that activates group VI iPLA2 through its influence on nuclear export. By inhibiting CRM1, Leptomycin B indirectly promotes group VI iPLA2 activation, leading to increased arachidonic acid release and lipid signaling. | ||||||